Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/jmv.28867 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Comprehensive Review on the Intricate Interplay between COVID-19 Immunization and the New Onset of Pemphigus Foliaceus.
Vaccines (Basel)
July 2024
Department of Oncologic Dermatology, "Elias" Emergency University Hospital, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.
Autoimmune bullous diseases (AIBDs) are characterized by the formation of vesicles, bullous lesions, and mucosal erosions. The autoantibodies target the cellular anchoring structures from the surface of epidermal keratinocyte named desmosomes, leading to a loss of cellular cohesion named acantholysis. AIBDs are classified into intraepidermal or subepidermal types based on clinical features, histological characteristics, and immunofluorescence patterns.
View Article and Find Full Text PDFDirect immunofluorescence on plucked hair outer root sheath can predict relapse in pemphigus vulgaris.
Int J Dermatol
July 2024
Department of Dermatology, Venereology and Leprology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Background: Prospective research is lacking on the utility of plucked hair outer root sheath direct immunofluorescence (ORS DIF) in the prediction of relapse in pemphigus vulgaris (PV) and the correlation of ORS DIF positivity with serum desmoglein antibody titers.
Methods: We performed a prospective cohort study enrolling 80 PV patients in complete clinical remission at a tertiary care center in North India. Study participants underwent ORS DIF at baseline, which was repeated every 3 months.
New Onset and Exacerbation of Autoimmune Bullous Dermatosis Following COVID-19 Vaccination: A Systematic Review.
Vaccines (Basel)
April 2024
Department of Dermatology, Chang Gung Memorial Hospital, Linkou Main Branch, Taoyuan 33305, Taiwan.
Article Synopsis
- Autoimmune bullous dermatosis (AIBD) cases have been observed in patients after receiving COVID-19 vaccinations, prompting a systematic review of their characteristics and outcomes.
- The review analyzed 98 studies involving 229 new-onset AIBD cases (mostly bullous pemphigoid) and 216 flare cases (predominantly pemphigus), with mRNA vaccines being a common link.
- Most AIBD cases emerged within 1 to 123 days after vaccination, with many patients experiencing favorable outcomes, highlighting the need for healthcare professionals to monitor post-vaccination effects carefully.
New-onset of pemphigus following COVID-19 infection: A case report.
SAGE Open Med Case Rep
February 2024
Division of Dermatology, The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada.
Article Synopsis
- * A case study discusses a patient whose pemphigus was triggered by COVID-19, showing improvement with treatments like prednisone and mycophenolate mofetil after 9 months.
- * The unique histological findings prompted the hypothesis that COVID-19 may lead to the release of pemphigus antigens, and clinicians should be cautious about distinguishing it from paraneoplastic pemphigus, especially when specific staining patterns are observed.
Autoimmune bullous disorder flares following severe acute respiratory syndrome coronavirus 2 vaccination: a case series.
J Med Case Rep
September 2023
University of Minnesota Medical School, Minneapolis, MN, USA.
Background: Autoimmune bullous disorders develop due to autoantibodies targeting intercellular adhesion proteins of hemidesmosomes and desmosomes and may be triggered by viral infections and vaccines. Recent reports suggest that the coronavirus disease 2019 vaccination may trigger flares or exacerbations of preexisting autoimmune diseases, including new onset autoimmune bullous disorders. There are less data on whether vaccination against severe acute respiratory syndrome coronavirus 2 may also exacerbate preexisting autoimmune bullous disorders.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!